Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years
Latest Information Update: 10 Dec 2016
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Influenza virus vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- 02 Dec 2016 Immunogenicity and safety results (n=1149) published in the Vaccine
- 31 Mar 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Aug 2014 New trial record